Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
LongevityInvestigational

Gerontin (Pineal Gland Extract)

Subcutaneous injection
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Gerontin refers to peptide fractions derived from pineal gland extracts studied primarily in Russian gerontology research. These preparations are hypothesized to contain bioactive peptides that regulate circadian rhythms, antioxidant defenses, and neuroendocrine aging processes.

Mechanism of Action

The pineal gland's role in melatonin synthesis and circadian coordination provides a biological rationale for investigating pineal-derived factors in aging. Gerontin formulations are not standardized, and active components have not been fully characterized by modern analytical methods.

Research Summary & Key Findings

Published studies on gerontin are largely confined to Russian-language literature and report lifespan extension and tumor suppression in rodent models of aging. Peer-reviewed replication in Western journals and rigorous clinical trials are lacking, limiting independent verification of reported effects. The lack of chemical characterization, regulatory approval, and controlled human data leaves gerontin's clinical utility unestablished.

Clinical Status

Investigational

Gerontin (Pineal Gland Extract) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injection

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Longevity

No lawful pathway today

Gerontin (Pineal Gland Extract) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.